Open AccessRisk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention
Author(s) -
John H. Alexander,
Daniel Wojdyla,
Amit N. Vora,
Laine Thomas,
Christopher B. Granger,
Shaun G. Goodman,
Ronald Aronson,
Stephan Windecker,
Roxana Mehran,
Renato D. Lópes
Publication year - 2020
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.120.046534
Subject(s) - medicine , apixaban , aspirin , percutaneous coronary intervention , atrial fibrillation , acute coronary syndrome , cardiology , placebo , randomization , vitamin k antagonist , randomized controlled trial , anesthesia , warfarin , myocardial infarction , rivaroxaban , alternative medicine , pathology
In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin. However, the number of ischemic events was numerically higher with placebo. The aim of this analysis is to assess the tradeoff of risk (bleeding) and benefit (ischemic events) over time with apixaban versus VKA and aspirin versus placebo.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom